(Q38496208)

English

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study

scientific article published on 03 January 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

0 references

4

object named as

Henry Krum

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Doron Aronson

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Joseph G Verbalis

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Matthias Mueller

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

DILIPO investigators

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

3 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

327-336

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Hyponatremia treatment guidelines 2007: expert panel recommendations

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Vasopressin antagonism in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Vasopressin antagonists: role in the management of hyponatremia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Whole-body volume regulation and escape from antidiuresis

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Non-peptide arginine-vasopressin antagonists: the vaptans

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Treatment of symptomatic hyponatremia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Brain volume regulation in response to hypo-osmolality and its correction

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ226

21 January 2018

Identifiers

10.1093/EURJHF/HFQ226

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38496208&oldid=1762303491"